Ronald Innerfield

Dr. Ronald Innerfield MD

Vice President of Clinical Affairs, Evidence Based Medicine, Inc.


          What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Member of the Healthcare Council

Request a consultation with Ronald Innerfield

Council Member Biography

Ronald Innerfield, MD, FACE, is Chief of Clinical Trials and Epidemiology, Emeritus, at the Dorothy Bullock Memorial National Diabetes Center. He is also Vice President of Clinical Affairs of Evidence Based Medicine, a site management organization (SMO) in Princeton. Dr. Innerfield was a Primary Medical Reviewer at the Division of Metabolic and Endocrine Drug Products (HFD-410) at CDER/FDA and Associate Director of Medical Research in the Metabolic/GI Division of Bayer, Inc., and Senior Medical Director at PharmaNet, a leading CRO. He also maintains an active clinical practice in New York's Hudson River Valley. Dr. Innerfield is well recognized in the field of diabetes, on the editorial board of Cardiovascular Diabetology, and has authored several book chapters and peer-reviewed journal articles. He is also a member of several of professional societies, including EASD, The Endocrine Society, the ADA, AMA, and AACE. (This is me - Update Profile)


Employment History

2005 - Unspecified
Vice President of Clinical Affairs, Evidence Based Medicine, Inc.
1994 - Unspecified
Chief of Clinical Trials and Epidemiology , The Dorothy Bullock Memorial National Diabetes Center
1990 - Unspecified
Physician, Diabetes & Metabolism, PC
1990 - 1994
Medical Officer, FOOD & DRUG ADMINISTRATION

GLG NewsSM Analyses by Ronald Innerfield

Opinions and analyses expressed in G+ Insights are solely those of the author. See the Terms of Use for details.


GLG News is now G+ Insights

G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.

Metanalyses, Metapsychoses

September 30, 2009

Controls to blood sugar 'cuts stroke risk' | www.barchester.com

There have been many epidemiologic studies showing a very tight correlation between baseline A1c and cardiovascular mortalityDespite this, five major randomized prospective studies have failed to show any macrovascular benefit for tighter glucose controlThe logical conclusion is that glucose is, therefore, a marker for increased mortality but not a modifiable risk factor thereofThis is why FDA has mandated cardiovascular safety for new antidiabetic agentsData dredging persists, however

GLG Live Meetings with Ronald Innerfield(?)

Recent Seminars

May 22, 2008 | Boston

GLG Seminar: Diabetes and Obesity

June 20, 2007 | Chicago

GLGi: Diabetes and Obesity

June 19, 2007 | New York

GLGi: Diabetes and Obesity Grand Rounds